Anti‐tumour efficacy on glioma models of <scp>PHA</scp>‐848125, a multi‐kinase inhibitor able to cross the blood–brain barrier
Clara Albanese(University of L'Aquila), Marina Ciomei(Nerviano Medical Sciences), MG Brasca(Nerviano Medical Sciences), Ciro Mercurio(Mylan (Switzerland)), Anna Degrassi(Nerviano Medical Sciences), Wilma Pastori(Nerviano Medical Sciences), Giovanni Luca Gravina(University of L'Aquila), Rachele Alzani(Nerviano Medical Sciences), Enrico Pesenti, Francesco Fiorentini(Nerviano Medical Sciences), Claudio Festuccia(University of L'Aquila), Arturo Galvani(Nerviano Medical Sciences), Nadia Amboldi(University of Pavia)
Cited by 21
Related Papers
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis.
|Proceedings of the National Academy of Sciences|1995|205
The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
|Molecular Oncology|2014|156
Identification of <i>N</i>,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1<i>H</i>-pyrazolo[4,3-<i>h</i>]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
|Journal of Medicinal Chemistry|2009|128
Afatinib Is a New Therapeutic Approach in Chordoma with a Unique Ability to Target EGFR and Brachyury
|Molecular Cancer Therapeutics|2017|93